Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

被引：15

作者：

Breitkreutz, I. ^{[1
,2
,3
]}

Heiss, C. ^{[4
]}

Perne, A. ^{[4
]}

Beimler, J. ^{[5
]}

Jaeger, D. ^{[3
]}

Egerer, G. ^{[4
]}

Ho, A. D. ^{[4
]}

Neben, K. ^{[4
]}

Zeier, M. ^{[5
]}

Goldschmidt, H. ^{[3
,4
]}

Raab, M. S. ^{[1
,2
,4
]}

机构：

[1] Univ Heidelberg Hosp, Max Eder Grp Expt Therapies Hematol Malignancies, D-69120 Heidelberg, Germany

[2] German Canc Res Ctr, Heidelberg, Germany

[3] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

[4] Univ Heidelberg Hosp, Dept Med 5, D-69120 Heidelberg, Germany

[5] Univ Heidelberg Hosp, Div Nephrol, D-69120 Heidelberg, Germany

来源：

BONE MARROW TRANSPLANTATION | 2014年 / 49卷 / 11期

关键词：

STEM-CELL TRANSPLANTATION; PRESENTING FEATURES; THERAPY; REVERSIBILITY; CHEMOTHERAPY; IMPAIRMENT; DIAGNOSIS; SAFETY;

D O I：

10.1038/bmt.2014.165

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Patients with multiple myeloma and dialysis-dependent renal failure have dismal outcomes. In this retrospective analysis of a case series, we evaluated 27 consecutive patients, all of whom required haemodialysis at the time of first-line induction therapy with either bortezomib or a standard regimen followed by high-dose chemotherapy and auto-SCT. The overall response rate was significantly better after bortezomib-based induction before auto-SCT (83% vs 36%, P = 0.02) and at day +100 post auto-SCT (100% vs 58%, P = 0.01). Bortezomib also prolonged EFS and furthermore, a trend towards a shorter time on haemodialysis was observed in the bortezomib group at a median of 6.1 months (0.2-68.2 months) vs 17.1 months (0.7-94.3 months, P = 0.38) in patients who had received vincristine, adriamycin, dexamethasone or vincristine, adriamycin, dexamethasone-like induction regimens. These data demonstrate the superior efficacy of bortezomib-based induction therapy in transplant-eligible patients with end-stage renal failure.

引用

页码：1371 / 1375

页数：5

共 21 条

[1] Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].

Augustson, BM ;

Begum, G ;

Dunn, JA ;

Barth, NJ ;

Davies, F ;

Morgan, G ;

Behrens, J ;

Smith, A ;

Child, JA ;

Drayson, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226

[2] Results of autologous stem cell transplant in multiple myeloma patients with renal failure [J].

Badros, A ;

Barlogie, B ;

Siegel, E ;

Roberts, J ;

Langmaid, C ;

Zangari, M ;

Desikan, R ;

Shaver, MJ ;

Fassas, A ;

McConnell, S ;

Muwalla, F ;

Barri, Y ;

Anaissie, E ;

Munshi, N ;

Tricot, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) :822-829

[3] Renal failure in multiple myeloma -: Presenting features and predictors of outcome in 94 patients from a single institution [J].

Bladé, J ;

Fernández-Llama, P ;

Bosch, F ;

Montoliu, J ;

Lens, XM ;

Montoto, S ;

Cases, A ;

Darnell, A ;

Rozman, C ;

Montserrat, E .

ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (17) :1889-1893

[4] Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [J].

Chanan-Khan, Asher A. ;

Kaufman, Jonathan L. ;

Mehta, Jayesh ;

Richardson, Paul G. ;

Miller, Kena C. ;

Lonial, Sagar ;

Munshi, Nikhil C. ;

Schlossman, Robert ;

Tariman, Joseph ;

Singhal, Seema .

BLOOD, 2007, 109 (06) :2604-2606

[5] The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma [J].

Dimopoulos, M. A. ;

Roussou, M. ;

Gkotzamanidou, M. ;

Nikitas, N. ;

Psimenou, E. ;

Mparmparoussi, D. ;

Matsouka, C. ;

Spyropoulou-Vlachou, M. ;

Terpos, E. ;

Kastritis, E. .

LEUKEMIA, 2013, 27 (02) :423-429

[6] Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment [J].

Dimopoulos, Meletios A. ;

Christoulas, Dimitrios ;

Roussou, Maria ;

Kastritis, Efstathios ;

Migkou, Magdalini ;

Gavriatopoulou, Maria ;

Matsouka, Charis ;

Mparmparoussi, Despoina ;

Psimenou, Erasmia ;

Grapsa, Irini ;

Efstathiou, Eleni ;

Terpos, Evangelos .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (01) :1-5

[7] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[8] Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT [J].

Glavey, S. V. ;

Gertz, M. A. ;

Dispenzieri, A. ;

Kumar, S. ;

Buadi, F. ;

Lacy, M. ;

Hayman, S. R. ;

Dingli, D. ;

McCurdy, A. ;

Hogan, W. J. ;

Gastineau, D. A. ;

Leung, N. .

BONE MARROW TRANSPLANTATION, 2013, 48 (12) :1543-1547

[9] Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre [J].

Haynes, Richard J. ;

Read, Simon ;

Collins, Graham P. ;

Darby, Sarah C. ;

Winearls, Christopher G. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (02) :419-426

[10] Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis [J].

Hutchison, Colin A. ;

Bradwell, Arthur R. ;

Cook, Mark ;

Basnayake, Kolitha ;

Basu, Supratik ;

Harding, Stephen ;

Hattersley, John ;

Evans, Neil D. ;

Cl-Lappel, Mike J. ;

Sampson, Paul ;

Foggensteiner, Lukas ;

Adu, Dwomoa ;

Cockwell, Paul .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (04) :745-754

← 1 2 3 →